Andrea Necchi

Profession:
Oncologist
Languages:
EN
IT

Biography

Professor Andrea Necchi is a medical oncologist at the Medical Oncology Unit of the IRCCS San Raffaele Hospital, directed by Professor Stefano Cascinu. He is also responsible for the medical treatment of genitourinary tumors (kidney, bladder, prostate, testicular tumors, and rare urological tumors).

He is an associate professor of Medical Oncology at the Vita-Salute San Raffaele University in Milan.

His educational background began with a degree in Medicine and Surgery with honors in 2004 from the University of Milan, followed by a specialization with honors in Medical Oncology in 2008 from the same university. During his specialization, he undertook specific training in the treatment of hematological malignancies and high-dose chemotherapy for solid tumors. Additionally, he began to focus on the multidisciplinary treatment of urological tumors.

Clinically and in research, Professor Necchi primarily focuses on the treatment of urological malignancies. Throughout his career, he has been one of the first in the world to develop the strategy of pre-operative immunotherapy for infiltrating bladder tumors and has gained significant clinical and research experience in testicular and penile malignancies.

Recently, under his coordination, his research group has initiated clinical studies targeting kidney and prostate tumors. The group is certified to conduct phase I studies aimed at treating patients with urological malignancies. Currently, there are approximately 30 clinical research protocols available to patients within the Unit. All clinical and translational research activities are carried out through a multidisciplinary approach, with close collaboration, particularly with the Urology Unit.

Throughout his career, he has received several awards, including:

  • July 2011: 1st Gianni Bonadonna Prize for New Drug Development in Oncology from the Michelangelo Foundation.  
  • November 2010: Young Researchers Award from the IRCCS National Cancer Institute of Milan.  
  • May 2012, September 2012, February 2013, February 2015: 4 Merit Awards from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO).  
  • 2018, 2019: 2 Merit Awards from the European Society for Medical Oncology (ESMO).  

He is a member of the Scientific Committee for the annual meetings of the following international associations:

  • American Society of Clinical Oncology (ASCO)  
  • European Society for Medical Oncology (ESMO)  
  • European Association of Urology (EAU)  
  • Society of Urologic Oncology (SUO)  
  • Société Internationale d’Urologie (SIU)  
  • European Multidisciplinary Urologic Meeting (EMUC)  

He is also a member of the Global Steering Committee for phase 2 and 3 clinical studies in urological malignancies and a co-founder and vice-president of the Global Society of Rare Genitourinary Tumors, an international organization dedicated to research, education, and information on rare genitourinary malignancies. He is a board member of the European Association of Urology – Research Foundation (EAU-RF).

He co-founded an Italian association dedicated to bladder tumors, Palinuro (Patients Free from Urothelial Tumors), and collaborates with ANTURE (National Association of Kidney Tumors).

He is the author and co-author of 299 publications in scientific journals and book chapters, with an H index of 36.

Read moreRead less

Do you need an appointment?

Contact us and we will take care of you.

Publications

Latest publications

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
J Clin Oncol. 2018 Dec 1;36(34):3353-3360.
Necchi A, Anichini A, Raggi D, et al.
Impact of Molecular Subtyping and Immune In ltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
Eur Urol. 2020 Jun;77(6):701-710.
Necchi A, Raggi D, Gallina A, et al.
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy?
First survival outcomes from the PURE-01 study. Ann Oncol. 2020 Dec;31(12):1755-1763.
Bandini M, Gibb EA, Gallina A, et al.
Erda tinib in Locally Advanced or Metastatic Urothelial Carcinoma
N Engl J Med. 2019 Jul 25;381(4):338-348.
Loriot Y, Necchi A, Park SH, et al.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Lancet Oncol 2012;8:810-16.
Necchi A, Mariani, Zaffaroni N, et al.
Proof of activity of anti-EGFR targeted therapy for relapsed squamous-cell carcinoma of the penis
J Clin Oncol 2011;29:2178-84.
Necchi A, Nicolai N, Colecchia C et al.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
N Engl J Med. 2017 Mar 16;376(11):1015-1026.
Bellmunt J, de Wit R, Vaughn DJ, et al.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatinineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol
2021 Jun;22(6):872-882.
Yu EY, Petrylak DP, O'Donnell PH, et al.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol. 2020 Dec;21(12):1574-1588.
Powles T, van der Heijden MS, Castellano D, et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Lancet Oncol. 2017 Mar;18(3):312-322.
Sharma P, Retz M, Siefker-Radtke A, et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Lancet. 2016 May 7;387(10031):1909-20.
Rosenberg JE, Hoffman-Censits J, Powles T, et al.
Atezolizumab as  rst-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet. 2017 Jan 7;389(10064):67-76.
Balar AV, Galsky MD, Rosenberg JE, et al.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Lancet. 2017 Nov 18;390(10109):2266-2277.
Petrylak DP, de Wit R, Chi KN, et al.
Contrasting genomic pro les from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer
Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865. Online ahead of print.
Necchi A, Cucchiara V, Grivas P, et al.
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumabur
Eur Urol. 2021 Aug;80(2):149-159.
Necchi A, de Jong JJ, Raggi D, et al.

Do you need an appointment?

Contact us and we will take care of you.